The Fed Backs Your Portfolio

By Ray BlancoPosted June 18, 2020

The federal government has money burning a hole in its pocket… And that’s very good for our portfolio! The Trump administration is preparing a proposal to spend a whopping $1 trillion on infrastructure. It’s not just to jump-start a COVID-19-ravaged economy, either…

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication(s) below and get access today!

Technology Profits Confidential

With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.

Technology Profits Confidential Pro

Ray Blanco’s VIP Tech Advantage

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, Ray Blanco’s FDA Trader, Penny Pot Profits, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2019, his closed positions in Technology Profits Confidential outperformed the S&P500 by 50%.

View More By Ray Blanco

Biotech Bonanza of 2012

By Ray BlancoPosted September 7, 2012

So far, 2012 has been a terrific year for our biotechnology portfolio. It's been great for biotech investors in general, despite the weak global economy. The NASDAQ Biotechnology Index (NBI), for example, is up 35%. Our newsletter's biotech picks, however, have outperformed even these stellar returns. Of the stocks we picked before January of this year, the average year to date return has been 58%. If we include our new picks, the figure comes out to 44.8%, year to date.

Betting Big on Blockchain

By Ray BlancoPosted January 19, 2018

One of the best ways to get a real pulse on big opportunities in the market is to pack your bags and hit the road. This week, I’m in San Francisco for the World Crypto Economic Forum…

Flash Sell: Book 100% Gain on This Biotechnology Company

By Ray BlancoPosted April 19, 2013

To borrow a line from a classic Steve Miller rock hit, it's time to “take the money and run.” Last night, my feed lit up with news about one company that reported great Phase 2 data for its follow-on cystic fibrosis drug VX-661. After-hours, the shares shot up by over 50%. We originally recommended selling half the company's shares in June 2011 for a 60% gain, after which it dropped to under $30 in November of that year. Share prices recovered in 2012 and have been trading between $40-60 since. Last night's news pushed its share price to over $80. This puts us at an over 100% gain -- good news in this dropping market.

Qualcomm Versus Apple: Game, Set, Match.

By Ray BlancoPosted April 19, 2019

The U.S. and the West in general are in a 5G race with China. The stakes are huge. 5G will enable new technologies, the shape of which we don’t even know yet…

Here We Go! Scientific Conference Heats up These Biotechs

By Ray BlancoPosted December 15, 2017

It was a roller coaster of a week for many biotechnology names. Many companies working on blood-related therapies participated at this year’s meeting of the American Society of Hematology. Investors got fresh looks at clinical data that had never been revealed before. In some cases, surprises pushed biotech shares down...in others, however, they went to the moon.

Multibillion Dollar Potential For Your Position

By Ray BlancoPosted May 8, 2020

Remdesivir has huge potential. And even though the company behind it is giving it away for free… there’s still huge potential in the future for a multibillion dollar potential.

Login